Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.
IPO Year:
Exchange: NASDAQ
Website: mindmed.co
Date | Price Target | Rating | Analyst |
---|---|---|---|
5/29/2024 | $27.00 | Outperform | Robert W. Baird |
4/15/2024 | $20.00 | Outperform | Leerink Partners |
12/5/2023 | $9.00 | Buy | Canaccord Genuity |
12/9/2022 | $25.00 | Buy | ROTH Capital |
11/16/2022 | $5.00 | Outperform | RBC Capital Mkts |
8/26/2022 | $3.50 | Outperform | Oppenheimer |
8/10/2022 | $3.00 | Overweight | Cantor Fitzgerald |
5/4/2022 | $7.00 | Buy | ROTH Capital |
8/5/2021 | $10.00 | Buy | HC Wainwright & Co. |
6/28/2021 | $6.00 | Buy | Maxim Group |
- New patent covers MM120 ODT formulation and extends patent term to 2041- - Claims include pharmaceutical formulation, methods of manufacturing and methods of treatment for MM120 ODT- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat mental health disorders, today announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering MM120 (lysergide). MM120 is currently in clinical development for adults with generalized anxiety disorder (GAD) and presents opportunities for treating a range of additional brain health disorders. The newly is
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective today. "MindMed's inclusion in the Russell Indexes mark an exciting milestone and reflects growing recognition of our commitment to addressing the unmet medical needs for people with brain health disorders by advancing MM120 for the treatment of general anxiety disorder and MM402 for the treatment of autism
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference being held on June 27, 2024. A webcast of the fireside chat will be accessible on MindMed's Investor Relations website starting on June 27, 2024 at 7:00 AM ET and will remain available for replay on the website for up to 90 days following the event. About MindMed MindMed is a clinical stage biopharmaceutical company developing novel product candidates to trea
-Aligned on requirements for Phase 3 clinical development of MM120 for the treatment of GAD- -Initiation of Phase 3 program remains on schedule to begin in second half of 2024- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the completion of the End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA), supporting the advancement of MM120 (lysergic acid diethylamide [LSD] D-tartrate) into pivotal trials for the treatment of adults with GAD. "Following a constructive End-of-Phase 2 meeting with the FDA, we are ple
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will participate in the following conferences: BIO International Convention 2024 Panel Name: Challenging Biotech's One-Track Mind When it Comes to Neuropsychiatric Drug Innovation Date and Time: Tuesday, June 4, 2024 at 4:15 pm PDT Location: San Diego, CA Jefferies 2024 Global Healthcare Conference Format: 1x1 investor meetings only Dates: June 5-6, 2024 Location: New York, NY About MindMed MindMed is a clinical st
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will participate in the following investor conferences: 2024 RBCCM Global Healthcare Conference Format: Fireside Chat Date and Time: Wednesday, May 15, 2024 at 11:00 am EDT Location: New York, NY Webcast Link: 2024 RBCCM Global Healthcare Conference HCW's 2nd Annual BioConnect Investor Conference Format: 1x1 investor meetings only Date: May 20, 2024 Location: New York, NY An audio webcast and replay of the firesid
--Announced positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), demonstrating clinically and statistically significant activity through 12 weeks after treatment-- --The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to MM120 for the treatment of GAD in adults-- --Cash and cash equivalents of $252.3 million as of March 31, 2024-- --Company to host a conference call today at 4:30 p.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for
-A single oral administration of MM120 100 µg met its primary and key secondary endpoints and maintained clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and a 48% clinical remission rate- -MindMed also presents two new epidemiology studies quantifying the burden of GAD in the US- -APA Annual Meeting, the largest psychiatric gathering in the world, is the first scientific presentation of MM120 Phase 2b data- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today presented data
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company's results for the first quarter ended March 31, 2024. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, https://ir.mindmed.co/, and archived for at least 30 days afte
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences: American Psychiatric Association (APA) 2024 Congress, New York, NY Title: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study Format: Poster Presenter: Dan Karlin, MD Date: Saturday, May 4
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
4 - Mind Medicine (MindMed) Inc. (0001813814) (Issuer)
8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
S-3ASR - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
S-8 - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
144 - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
10-Q - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
8-K - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
424B3 - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
424B3 - Mind Medicine (MindMed) Inc. (0001813814) (Filer)
SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
SC 13G/A - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
SC 13G - Mind Medicine (MindMed) Inc. (0001813814) (Subject)
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced today that as part of the annual reconstitution of the Russell stock indexes, the Company will be included in the Russell 2000® Index and the broad-market Russell 3000® Index, effective today. "MindMed's inclusion in the Russell Indexes mark an exciting milestone and reflects growing recognition of our commitment to addressing the unmet medical needs for people with brain health disorders by advancing MM120 for the treatment of general anxiety disorder and MM402 for the treatment of autism
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the appointment of Mark R. Sullivan, effective today, as Chief Legal Officer and Corporate Secretary. "We are very excited to welcome Mark to our management team. Mark brings tremendous legal and public company life sciences expertise and will be a strong addition to our executive team. We believe Mark's experience, insights and guidance will prove invaluable as MindMed progresses to the next stage of its evolution. I look forward to working closely with Mark during this transf
NEW YORK, Aug. 12, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Dr. Suzanne Bruhn and Dr. Roger Crystal, effective August 11, 2022 as independent members of its Board of Directors. "We are pleased to welcome both Dr. Bruhn and Dr. Crystal to our Board. Their collective life sciences experience will be invaluable as we advance through several key product development inflection points in the com
FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 10, 2022 /PRNewswire/ -- Toronto's Center for Addiction and Mental Health (CAMH) just received the first-ever federal grant to study whether the active component of "magic" mushrooms can be used to treat depression. Researchers will explore whether the psychoactive effects are necessary to relieve treatment-resistant depression in adults. According to CAMH's lead investigator, clinical trials suggest that psilocybin, combined with psychotherapy, can produce "sustained antidepressant effects" in individuals living with severe depression. This news comes just days after a major scientific review found "no clear evidence
NEW YORK, June 1, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company" or "MindMed"), announces the voting results of the Company's annual general and special meeting of shareholders held on June 1, 2022 (the "Meeting"). Election of DirectorsThe five nominees of management were elected as directors at the Meeting. The voting results for the election of each director nominee are as follows: Name of Nominee Votes For Votes Withheld Number of Votes Percentage of Votes Number of Votes Percentage of Votes Carol A. Vallone 66,244,518.68 89.04%
NEW YORK, May 23, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced the appointment of Schond L. Greenway as Chief Financial Officer. Mr. Greenway comes to MindMed with over 20 years of experience in investment banking, finance and corporate advisory, and investment analysis in the life sciences sector. "We are very excited to add Schond to our management team. Schond brings extensive expertise in US biotech ca
- Dr. Lilienthal brings over 20 years of global biopharmaceutical experience, leading the development and commercialization of innovative medicines across multiple therapeutic areas including psychiatry and neurology - NEW YORK, April 5, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced the appointment of Francois Lilienthal, MD as Chief Commercial Officer. With more than two decades of global biopharmaceutical experience and after serving as a consultant for MindMed over the past six months, Dr. Lilienthal will step into this role to support the
NEW YORK, Jan. 7, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-derived therapies, announces the resignation of Stephen Hurst from his role as a Director of the Company's Board of Directors. "On behalf of MindMed, the Board of Directors, and the Executive team, I thank Steve for his significant contributions and strategic guidance in bringing the Company to this stage of development," said Robert Barrow, Chief Executive Officer and Director of MindMed. "The co-founders a
-Mr. Barrow previously served as interim Chief Executive Officer and Chief Development Officer of MindMed -Carol Vallone appointed as Chair of the Board of Directors, Andreas Krebs appointed as Vice Chair and Perry Dellelce transitions from his role as Chairman- NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that Robert Barrow was appointed as Chief Executive Officer and as a member of the Board of Directors, effective immediately. Mr. Barrow previously served as interim Chief Executive Officer and Chief Development Officer of Min
NEW YORK, Nov. 5, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (NEO: MMED) (DE: MMQ) the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the appointment of Maria A. Oquendo, M.D., Ph.D. to its Scientific Advisory Board. Dr. Oquendo is Ruth Meltzer Professor and Chairman of Psychiatry at University of Pennsylvania and Psychiatrist-in-Chief at the Hospital of the University of Pennsylvania. A summa cum laude graduate of Tufts University, she attended Vagelos College of Physicians and Surgeons at Columbia
https://www.greenmarketreport.com/mdma-therapy-gets-support-from-prominent-research-group-as-fda-weighs-action/ The paper noted that MDMA therapies have been proven safe and effective by multiple studies.As an August deadline for the U.S. Food and Drug Administration looms regarding approval for psychedelic therapies, a coalition of well-known scientific researchers took it upon itself to publicize its support for midomafetamine (MDMA)-based treatment for patients with post-traumatic stress disorder.In an online consensus statement, 23 medical doctors and researchers urged the FDA to accept MDMA therapy for PTSD, noting that more than 17 U.S. military veterans commit suicide each day due to
https://www.marijuanamoment.net/california-legislature-approves-bill-to-break-psychedelics-research-logjam-sending-it-to-governor/
A promising new startup, Ovax Inc., secured $10 million in funding to advance the development of a groundbreaking vaccine designed to prevent fentanyl-related deaths. The initiative focuses on commercializing academic research aimed at preventing the potent opioid from reaching the brain, reported Bloomberg on Wednesday. Ovax obtained licensing for intellectual property from University of Houston researchers who successfully tested a fentanyl vaccine in rats. The company, which officially launches this week, is set to begin human trials early next year. If successful, the vaccine would block the euphoric effects and deadly overdoses caused by fentanyl. Unlike naloxone, which can r
Cantor Fitzgerald analyst Charles Duncan reiterates Mind Medicine (NASDAQ:MNMD) with a Overweight.
Rob Barrow, Chief Executive Officer of MindMed, said, "This marks a significant milestone for MindMed and for the millions of individuals affected by GAD. We are on schedule to initiate our Phase 3 clinical program for MM120 oral dissolving tablet (ODT) in GAD in the second half of this year and look forward to sharing additional details on the design of our pivotal program in the coming months."
https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after-launching/"Unfortunately we've seen one service center close down. I imagine there will be more, because very quickly it's going to get oversaturated."By Grant Stringer, Oregon Capital ChronicleA year in, Oregon's experiment with the first regulated psilocybin mushroom market in the world is short on customers.To attract them, advocates say the industry needs to get the word out about its benefits."We think everybody knows that psychedelics can help them because we're in this little bubble. But 99 percent of people have no idea what they could get out of a journey,"
A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outweigh the risks of introducing the psychedelic treatment to patients. Most stocks in the psychedelic space took a hit on Wednesday as a result of the ruling.The panel voted 9-2 that MDMA, when combined with talk therapy, is not effective in treating PTSD. The panel also voted 10-1 that the current benefits do not outweigh the potential risks of using the drug to treat mental issues.Some members of the panel, like sociologist Elizabeth Joniak-Grant, pointed to allegations of misconduct in trials th
Shares of Lands’ End, Inc. (NASDAQ:LE) fell sharply during Wednesday's session following first-quarter results. Lands’ End reported quarterly adjusted loss of 20 cents per share which beat the analyst consensus estimate of 26 cents per share. The company reported quarterly sales of $285.47 million which beat the analyst consensus estimate of $269.82 million, according to data from Benzinga Pro. Lands’ End shares dipped 9.3% to $12.60 on Wednesday. Here are some other stocks moving in today’s mid-day session. Gainers Actelis Networks, Inc. (NASDAQ:ASNS) shares jumped 512% to $2.88 after the company announced orders for cyber-hardened networking technology to be deployed at thr
--Announced positive Phase 2b clinical trial results for MM120 in Generalized Anxiety Disorder (GAD), demonstrating clinically and statistically significant activity through 12 weeks after treatment-- --The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to MM120 for the treatment of GAD in adults-- --Cash and cash equivalents of $252.3 million as of March 31, 2024-- --Company to host a conference call today at 4:30 p.m. EDT-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced its financial results for
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Wednesday, May 8, 2024, at 4:30 p.m. ET to provide a corporate update and review the Company's results for the first quarter ended March 31, 2024. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the MindMed website, https://ir.mindmed.co/, and archived for at least 30 days afte
-A single oral administration of MM120 100 µg met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and 48% clinical remission rate- -MindMed plans to hold an End-of-Phase 2 meeting with the U.S. Food & Drug Administration (FDA) in the first half of 2024 and initiate its Phase 3 clinical program in the second half of 2024- -MindMed will host a webcast to discuss data from its Phase 2b study at 8:00 am ET- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product cand
- Data update includes 12-week topline Phase 2b results for MM120 in Generalized Anxiety Disorder (GAD) - - Results from Phase 1 pharmacokinetics bridging trial for MM120 oral dissolving tablet (ODT) formulation to be discussed - Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a conference call and webcast on March 7, 2024. The program will provide an update on MM120 in Generalized Anxiety Disorder (GAD), including 12-week topline safety, efficacy, and durability results from the Company's Phase 2
--Announced statistically significant and clinically meaningful topline Phase 2b data for MM120 at 4 weeks in Generalized Anxiety Disorder (GAD)-- --Multiple planned milestones for MM120 in GAD, including 12-week Phase 2b data to be presented at March 7th investor event, and initiation of Phase 3 clinical program in second half of 2024-- --Initiated Phase 1 clinical trial of MM402 in Autism Spectrum Disorder (ASD)-- --Conference call to discuss year-end financial results at 8:00 a.m. EST-- Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (Cboe Canada:MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health d
– Trial met its primary endpoint with MM-120 demonstrating a statistically significant dose-dependent improvement in HAM-A scores four weeks after a single-dose – – MM-120 100 µg demonstrated a clinically and statistically significant HAM-A reduction of 21.3 points, representing a 7.6-point improvement over placebo at Week 4 (p=0.0004, Cohen's d effect size = 0.88) – – Clinical response rate of 78% in 100 µg and 200 µg dose groups and 50% clinical remission rate in the 100 µg dose group at Week 4 – – MM-120 was generally well-tolerated with mostly mild-to-moderate adverse events that occurred on dosing day – – Company plans to hold an End-of-Phase 2 meeting with the U.S. Food & Drug
– Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 – – Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated by the end of Q1 2024 – – MM-402 in ASD on track for Phase 1 clinical trial initiation in Q4 2023 – – Cash and cash equivalents of $117.7 million at September 30, 2023 – – Company to host conference call today at 4:30 PM ET – Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today reported its financial results for the quarter ended September 30, 2023. "During the third quarter we continued
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Thursday, November 2, 2023, at 4:30 p.m. ET to provide a corporate update and review the Company's results for the quarter ended September 30, 2023. Individuals may participate in the live call via telephone by dialing (855) 327-6837 (domestic) or (631) 891-4304 (international). The webcast can be accessed live here on the Financials page in the Investors section of the MindMed website, https://mindmed.co/. The webcast will be archived
– Topline readout of MM-120 in GAD (Phase 2b) expected in Q4 2023 with enrollment to be concluded in Q3 2023 – – Topline readout of MM-120 in ADHD (Phase 2a proof-of-concept) anticipated in Q4 2023 / Q1 2024 – – MM-402 in ASD on track for Phase 1 clinical trial initiation in Q4 2023 – – Entered into exclusive license agreement with Catalent for MM-120 Zydis® orally disintegrating tablet (ODT) formulation for advancement into pivotal clinical trials – – Cash and cash equivalents of $116.9 million at June 30, 2023 – – Company to host conference call today at 4:30 PM ET – Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biophar
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it plans to host a conference call on Thursday, August 3, 2023, at 4:30 p.m. ET to provide a corporate update and review the Company's results for the quarter ended June 30, 2023. Individuals may participate in the live call via telephone by dialing (877) 407-3982 (domestic) or (201) 493-6780 (international). The webcast can be accessed live here on the Financials page in the Investors section of the MindMed website, https://mindmed.co/. The webcast will be archived on the
Robert W. Baird initiated coverage of MindMed with a rating of Outperform and set a new price target of $27.00
Leerink Partners initiated coverage of MindMed with a rating of Outperform and set a new price target of $20.00
Canaccord Genuity initiated coverage of MindMed with a rating of Buy and set a new price target of $9.00
ROTH Capital resumed coverage of MindMed with a rating of Buy and set a new price target of $25.00
RBC Capital Mkts initiated coverage of MindMed with a rating of Outperform and set a new price target of $5.00
Oppenheimer initiated coverage of MindMed with a rating of Outperform and set a new price target of $3.50
Cantor Fitzgerald initiated coverage of MindMed with a rating of Overweight and set a new price target of $3.00
ROTH Capital initiated coverage of MindMed with a rating of Buy and set a new price target of $7.00
HC Wainwright & Co. initiated coverage of Mind Medicine with a rating of Buy and set a new price target of $10.00
Maxim Group initiated coverage of MindMed with a rating of Buy and set a new price target of $6.00